透析患者的COVID-19:临床影响、免疫应答、预防与治疗
透析人群SARS-CoV-2感染与死亡风险增高,幸存者病毒脱落延长但多产生稳健持久且与初始病情严重度相关的体液免疫,再感染保护不完全。疫苗接种后免疫应答延迟且减弱,mRNA-1273免疫原性优于BNT162b2,腺病毒载体疫苗劣于mRNA疫苗;基础免疫后1至2个月内接种第三剂显著提高抗体水平,尤其初始应答差者。初步数据显示疫苗部分预防感染和需住院的重症,但免疫渐弱及免疫逃逸变异株出现,所有透析患者应在基础免疫后4至6个月接种加强针。
要点
- 透析患者SARS-CoV-2感染和死亡风险增高,再感染保护不完全。
- 透析患者对疫苗应答延迟且减弱,mRNA-1273免疫原性优于BNT162b2。
- 基础免疫后4至6个月应接种加强针,持续应答差者可考虑一级预防策略。
核心结论
- 透析患者COVID-19感染与死亡风险增高,疫苗免疫应答减弱,但初步数据提示疫苗部分预防感染和需住院的重症。
- 免疫渐弱和免疫逃逸变异株出现,所有透析患者应在基础免疫后4至6个月接种加强针。
- 持续疫苗应答差的患者可能是一级预防策略的候选者。
研究设计与样本
- 综述,汇总透析患者COVID-19临床影响、免疫应答、预防与治疗的已有证据。
主要发现
- 透析患者SARS-CoV-2感染和死亡风险增高,部分经历心理困扰及延迟或次优照护。
- COVID-19幸存者病毒脱落延长,但多产生稳健持久且与初始病情严重度相关的体液免疫,再感染保护不完全。
- 透析患者对SARS-CoV-2疫苗免疫应答延迟且减弱,基础免疫后1至2个月内接种第三剂显著提高抗体水平,尤其初始应答差者。
- 透析患者对腺病毒载体疫苗的免疫应答劣于mRNA疫苗,mRNA-1273免疫原性明显优于BNT162b2,可能因其mRNA含量更高。
- 初步数据提示疫苗部分预防感染和需住院的重症。
关键数值与推荐
- 基础免疫后1至2个月内接种第三剂显著提高抗体水平,尤其初始应答差者。
- 所有透析患者应在基础免疫后4至6个月接种加强针。
- 持续疫苗应答差的患者可能是一级预防策略的候选者。
- 中和单克隆抗体可在高风险暴露后或感染早期考虑使用。
临床怎么用
- 透析患者应在基础免疫后4至6个月接种加强针。
- 持续疫苗应答差的患者可考虑一级预防策略。
- 缺乏透析患者特定数据时,已确诊COVID-19的治疗策略须从非透析人群证据外推。
- 中和单克隆抗体可能是高风险暴露后或感染早期的一个有吸引力的选择。
局限性
- 再感染保护不完全。
- 透析患者疫苗免疫应答延迟且减弱。
- 疫苗部分预防感染和需住院重症仅为初步数据。
- 缺乏透析患者特定治疗数据,须从非透析人群证据外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has profound adverse effects on the population on dialysis. Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality, and many have experienced psychological distress as well as delayed or suboptimal care. COVID-19 survivors have prolonged viral shedding, but generally develop a robust and long-lasting humoral immune response that correlates with initial disease severity. However, protection against reinfection is incomplete. A growing body of evidence reveals delayed and blunted immune responses to SARS-CoV-2 vaccination. Administration of a third dose within 1 to 2 months of prime-boost vaccination significantly increases antibody levels, in particular in patients with poor initial responses. Patients on dialysis have inferior immune responses to adenoviral vector vaccines than to mRNA vaccines. The immunogenicity of the mRNA-1273 vaccine is markedly better than that of the BNT162b2 vaccine, most likely by virtue of its higher mRNA content. Despite suboptimal immune responses in patients on dialysis, preliminary data suggest that vaccination partially protects against infection and severe disease requiring hospitalization. However, progressive waning of immunity and emergence of SARS-CoV-2 variants with a high potential of immune escape call for a booster dose in all patients on dialysis 4 to 6 months after prime-boost vaccination. Patients with persistent poor vaccine responses may be candidates for primary prophylaxis strategies. In the absence of specific data in patients on dialysis, therapeutic strategies in the event of established COVID-19 must be extrapolated from evidence obtained in the population not on dialysis. Neutralizing monoclonal antibodies may be an attractive option after a high-risk exposure or during the early course of infection.
引用
- El Karoui K, De Vriese AS. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int. 2022. PMID: 35176326. doi:10.1016/j.kint.2022.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。